Market cap
$7,891 Mln
Recently Viewed
Clear All$300.78
$-4.89
(-1.60%)
As on 22-Apr-2026 16:00EDT
Market cap
$7,891 Mln
Revenue (TTM)
$2,583 Mln
P/E Ratio
10.5
P/B Ratio
1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$760 Mln
ROE
0.1 %
ROCE
9 %
Industry P/E
--
EV/EBITDA
6.3
Debt to Equity
0.2
Book Value
$275.9
EPS
$28.1
Face value
--
Shares outstanding
21,924,404
CFO
$3,324.47 Mln
EBITDA
$4,405.61 Mln
Net Profit
$6,268.10 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bio-Rad Laboratories Inc. Class A (BIO)
| -0.7 | 13.7 | -3.5 | 27.0 | -13.7 | -13.9 | 7.9 |
|
BSE Sensex*
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P Midcap 400
| 8.6 | 10.3 | 4.0 | 35.6 | 13.3 | 6.0 | 9.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Bio-Rad Laboratories Inc. Class A (BIO)
| -7.8 | 1.7 | -23.2 | -44.3 | 29.6 | 57.5 | 59.3 |
|
S&P Midcap 400
| 5.9 | 12.1 | 14.4 | -14.5 | 23.2 | 11.8 | 24.1 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bio-Rad Laboratories Inc. Class A (BIO)
|
300.8 | 7,890.9 | 2,583.2 | 759.9 | 25.2 | 10.8 | 10.5 | 1.0 |
| 91.7 | 168,225.1 | 45,134.0 | 6,276.0 | 15.4 | 24.6 | 26.7 | 3.2 | |
| 196.1 | 13,612.3 | 4,035.0 | 410.4 | 14.2 | 10.4 | 33.6 | 3.3 | |
| 18.3 | 9,659.1 | 11,244.0 | -957.0 | -1.9 | -14.6 | -- | 1.5 | |
| 95.0 | 12,546.1 | 2,938.9 | 537.9 | 18.3 | 12.3 | 23.7 | 2.8 | |
| 78.1 | 9,045.6 | 13,184.0 | 398.0 | 5.2 | 12 | 23.7 | 2.7 | |
| 483.6 | 166,649.2 | 10,064.7 | 2,856.0 | 29.3 | 16.7 | 59.5 | 9.1 | |
| 28.2 | 27,139.1 | 17,834.0 | 895.0 | 8.5 | 7.8 | 26.2 | 2.1 | |
| 138.8 | 5,764.2 | 1,992.7 | -905.6 | -2.3 | -24.5 | 98.7 | 1.8 | |
| 514.0 | 191,756.6 | 44,556.0 | 6,737.0 | 19.5 | 13.1 | 29.1 | 3.7 |
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science... and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. Address: 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 Read more
Chairman, CEO, President & Principal Financial Officer
Mr. Norman D. Schwartz
Chairman, CEO & President
Mr. Norman D. Schwartz
Headquarters
Hercules, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Bio-Rad Laboratories Inc Class A (BIO) is $300.78 (NYSE) as of 22-Apr-2026 16:00 EDT. Bio-Rad Laboratories Inc Class A (BIO) has given a return of -13.66% in the last 3 years.
The P/E ratio of Bio-Rad Laboratories Inc Class A (BIO) is 10.49 times as on 15-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
10.77
|
1.10
|
|
2024
|
-4.99
|
1.40
|
|
2023
|
-14.60
|
1.06
|
|
2022
|
-3.45
|
1.30
|
|
2021
|
5.31
|
1.65
|
The 52-week high and low of Bio-Rad Laboratories Inc Class A (BIO) are Rs 343.12 and Rs 211.43 as of 23-Apr-2026.
Bio-Rad Laboratories Inc Class A (BIO) has a market capitalisation of $ 7,891 Mln as on 15-Apr-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Bio-Rad Laboratories Inc Class A (BIO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.